Business soars for Korean pharma as U.S. cuts ties with Chinese partners
The United States' efforts to reduce reliance on Chinese biotechnologies are creating new opportunities for Korean biopharmaceutical companies, with Samsung Biologics and CHA Bio Group eyeing increased revenue.